Overview
Braveheart Bio Inc., a clinical‑stage biopharmaceutical company founded in 2024, completed its initial public offering on Thursday, listing on the Nasdaq Global Market under the ticker BRVE. The shares opened at $30.20 per share, representing a 68% increase over the IPO price of $18.
Offering Details
The IPO raised $382.5 million, giving the company a market valuation of approximately $2.13 billion based on outstanding shares. Investors contributed about $185 million, with notable participation from a16z’s biotech fund and Patient Square Capital.
Business Highlights
Braveheart Bio is developing BHB‑1893, its lead drug candidate targeting hypertrophic cardiomyopathy, an inherited condition that impairs cardiac pumping ability. The firm obtained licensing rights for BHB‑1893 from Jiangsu Hengrui Pharmaceuticals, a Chinese drugmaker.
Financial Performance
For the first quarter of 2026, Braveheart reported a net loss of $14.3 million and generated $11 million in revenue. In the comparable quarter of 2025, the company recorded a net loss of $99,000.
Governance and Underwriters
Christopher Viehbacher, CEO of Biogen Inc., serves as chairman of Braveheart Bio. The offering was underwritten by Goldman Sachs Group Inc., Jefferies Financial Group Inc., Toronto‑Dominion Bank, Stifel Financial Corp., and Cantor Fitzgerald.
Market Reaction
The strong debut price and substantial first‑day gain underscore investor enthusiasm for the company’s pipeline and capital raise.